Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 2/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473666 | 0.90 | CYP2A6 (0.37) | NPC1RAB9ACYP2A6CYP11B1CYP11B2 | |
| SCHEMBL473783 | 0.87 | CYP2A6 (0.42) | CYP2A6CYP11B1CYP11B2PTGDR2PIM1 | |
| SCHEMBL2216914 | 0.83 | CYP2A6 (0.38) | NPC1RAB9ACYP2A6CYP11B1CYP11B2 | |
| SCHEMBL2218828 | 0.80 | PIM1 (0.41) | CYP2A6CYP11B1CYP11B2PTGDR2PIM1 | |
| SCHEMBL12435499 | 0.80 | NPC1 (0.51) | NPC1RAB9ACYP2A6CYP11B1CYP11B2 | |
| SCHEMBL473708 | 0.79 | CYP2A6 (0.40) | CYP2A6CYP11B1CYP11B2PTGDR2PIM1 | |
| SCHEMBL2220367 | 0.79 | CYP2A6 (0.40) | CYP2A6CYP11B1CYP11B2PTGDR2PIM1 | |
| SCHEMBL2218482 | 0.77 | CYP2A6 (0.38) | CYP2A6CYP11B1CYP11B2PTGDR2PIM1 | |
| SCHEMBL1560920 | 0.76 | CYP11B1 (0.38) | CYP2A6CYP11B1CYP11B2PIM1CYP3A4 | |
| SCHEMBL11908027 | 0.76 | SLC2A1 (0.41) | CYP2A6CYP11B1CYP11B2PTGDR2CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | NPC1 3112/4885RAB9A 2029/4885CYP2A6 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.